**KG Jebsen Centre for Myeloid Blood Cancer C-MYC**

Opening Symposium

Venue: Grand Bergen, Nedre Ole Bulls plass 1, 5012 Bergen

**10:30 Registration, Coffee**

11:00-12:00 Opening

11:00-11:10 Bjørn Tore Gjertsen, C-MYC Centre Director

11:15-11:20 Anne Marie Haga, KG Jebsen Foundation

11:25-11:35 Olav Ljøsne, Chair, Blodkreftforeningen

11:35-11:40 Per Bakke, Dean, Medical Faculty, University of Bergen

11:45-11:50 Clara Gjesdal, vice CEO, Haukeland University Hospital

11:55-12:00 Silke Appel, Chair, Department of Clinical Sciences, University of Bergen

12:00-12:05 Kahtan Al-Azawy, Director, Department of Medicine, Haukeland University Hospital

**12:05-13:20 Lunch**

Scientific Program

13:20-14:00 **Targeting Epigenetics: A new strategy in myeloid cancer prevention?** Kirsten Grönbæk

14:00-14:40 **Molecular Measureable Residual Disease Monitoring in Acute Myeloid Leukemia (AML),** Konstanze Döhner

14:40-15:20 **What is meant by "responsible" cancer research?** Roger Strand, CCBIO, Centre for the Study of the Sciences and the Humanities

15:20-15:30 Concluding remarks and introduction of Symposium Day 2, Bjørn Tore Gjertsen

(Dinner, Hotel Norge, 19:00, Aperitif 18:30)

Thursday 12. September, Grand Bergen

**08:30 Registration, Coffee**

Chair: BT Gjertsen

09:00-09:20 **Demultiplexing cell identity**, Simona Chera, KGJ C-MYC

09:20-09:40 **Towards single-cell profiling of translation and isoforms**, Eivind Valen, KGJ C-MYC

09:40-10:00 **Minimal Residual disease in myelodysplastic syndrome**, Astrid Olsnes

10:00-10:20 **Allogeneic hematopoietic stem cell transplantation for myeloid malignancies - from patient’s bed to multiomics?** Håkon Reikvam

**10:20-10:30 Pause**

Chair: S Chera

10:30-10:50 **Novel approaches to the prevention of acute graft versus host disease,** Yngvar Fløisand

10:50-11:10 **AML modelling: Past, present and future directions**, Emmet Mc Cormack

11:10-11:30 **How can we make use of the p53 code in the clinic?** JC Bourdon

11:30-12:00  **Functional precision medicine for overcoming drug resistance in elderly/unfit AML patients**, Krister Wennerberg

**12:00-12:50 Lunch**

Chair: E Valen

12:50-13:10 **Generating evidence from Real World Data in hematology**, Kimmo Porkka

13:10-13:30 **Evolutionary landscape of clonal hematopoiesis**, Gerwin Huls

13:30-14:10 **Novel candidate targets for future AML therapies: Glycosaminoglycans and DNA-PK**, Kim Theilgaard-Mönch

14:10-14:30 **Targeting NAMPT in -7/-7q Myeloid Blood Cancers**, Caroline Heckman

**14:30-14:40 Pause**

Chair: H Reikvam

14:40-15:00 **Clinical forecasting of Acute Myeloid Leukemia by ex vivo drug sensitivity screening**, Jorrit Enserink

15:00-15:20 **Ex Vivo Venetoclax Sensitivity Testing Predicts Treatment Response in AML**, Mika Kontro

15:20-15:40 **A phase 1 study to study 5-FU-mir-15a (CR-001) in AML**, Andrea Lenartova

15:40-16:00 **Quality of life studies in AML in Sweden**, Vladimir Lazarevic

16:00-16:20 **Metabolic rewiring as targetable entity in AML**, JJ Schuringa

16:20-16:40 Closing remarks, Simona Chera (Co-Director, C-MYC)